LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 149

Search options

  1. Book: Pulmonary arterial hypertension

    Barst, Robyn J.

    diagnosis and evidence-based treatment

    2008  

    Author's details ed. by Robyn J. Barst
    Keywords Hypertension, Pulmonary / diagnosis ; Hypertension, Pulmonary / therapy ; Evidence-Based Medicine / methods ; Pulmonary Artery / pathology
    Language English
    Size XIII, 256 S., [4] Bl. : Ill., graph. Darst.
    Publisher Wiley
    Publishing place Chichester u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT015465020
    ISBN 978-0-470-05972-2 ; 0-470-05972-9
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2008 A 3059 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Classification of pediatric pulmonary hypertensive vascular disease: Does it need to be different from the adult classification?

    Barst, Robyn J

    Pulmonary circulation

    2011  Volume 1, Issue 2, Page(s) 134–137

    Language English
    Publishing date 2011-09-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2638089-4
    ISSN 2045-8940 ; 2045-8940
    ISSN (online) 2045-8940
    ISSN 2045-8940
    DOI 10.4103/2045-8932.83443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Children deserve the same rights we do: the need for paediatric pulmonary arterial hypertension clinical drug development.

    Barst, Robyn J

    Heart (British Cardiac Society)

    2010  Volume 96, Issue 17, Page(s) 1337–1338

    MeSH term(s) Adult ; Age Factors ; Antihypertensive Agents/therapeutic use ; Child ; Drug Discovery/methods ; Humans ; Hypertension, Pulmonary/drug therapy ; Treatment Outcome
    Chemical Substances Antihypertensive Agents
    Language English
    Publishing date 2010-09
    Publishing country England
    Document type Comment ; Editorial
    ZDB-ID 1303417-0
    ISSN 1468-201X ; 1355-6037
    ISSN (online) 1468-201X
    ISSN 1355-6037
    DOI 10.1136/hrt.2010.195248
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.40: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 112: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Pulmonary hypertension: past, present and future.

    Barst, Robyn J

    Annals of thoracic medicine

    2008  Volume 3, Issue 1, Page(s) 1–4

    Language English
    Publishing date 2008-12-05
    Publishing country India
    Document type Editorial
    ZDB-ID 2241287-6
    ISSN 1998-3557 ; 1817-1737
    ISSN (online) 1998-3557
    ISSN 1817-1737
    DOI 10.4103/1817-1737.37832
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: A review of pulmonary arterial hypertension: role of ambrisentan.

    Barst, Robyn J

    Vascular health and risk management

    2007  Volume 3, Issue 1, Page(s) 11–22

    Abstract: Pulmonary arterial hypertension (PAH) is a rare fatal disease. Current disease-specific therapeutic interventions in PAH target 1 of 3 established pathways in disease pathobiology: prostacyclin, nitric oxide, and endothelin-1. Endothelin receptor ... ...

    Abstract Pulmonary arterial hypertension (PAH) is a rare fatal disease. Current disease-specific therapeutic interventions in PAH target 1 of 3 established pathways in disease pathobiology: prostacyclin, nitric oxide, and endothelin-1. Endothelin receptor antagonists (ERAs) act on the endothelin pathway by blocking binding of endothelin-1 to its receptors (endothelin type-A [ET(A)] and/or type-B [ET(B)]) on the surface of endothelial and smooth muscle cells. Ambrisentan is an oral, once-daily, ET(A)-selective ERA in development for the treatment of PAH. In Phase 3 clinical trials in patients with PAH, ambrisentan (2.5-10 mg orally once-daily) improved exercise capacity, Borg dyspnea index, time to clinical worsening, WHO functional class, and quality of life compared with placebo. Ambrisentan provided durable (at least 2 years) improvement in exercise capacity in a Phase 2 long-term extension study. Ambrisentan was well tolerated with a lower incidence and severity of liver function test abnormalities compared with the ET(A)/ET(B) ERA, bosentan, and the ET(A)-selective ERA, sitaxsentan. Ambrisentan does not induce or inhibit P450 enzymes; therefore, ambrisentan is unlikely to affect the pharmacokinetics of P450-metabolized drugs. The demonstration of clinical efficacy, low incidence of acute hepatic toxicity, and low risk of drug-drug interactions support the role of ambrisentan for the treatment of PAH.
    MeSH term(s) Endothelin Receptor Antagonists ; Endothelin-1/blood ; Endothelin-1/drug effects ; Exercise/physiology ; Humans ; Hypertension, Pulmonary/blood ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/physiopathology ; Muscle, Smooth, Vascular/drug effects ; Muscle, Smooth, Vascular/physiopathology ; Phenylpropionates/pharmacokinetics ; Phenylpropionates/therapeutic use ; Pulmonary Wedge Pressure/drug effects ; Pulmonary Wedge Pressure/physiology ; Pyridazines/pharmacokinetics ; Pyridazines/therapeutic use ; Receptors, Endothelin/blood ; Treatment Outcome ; Vascular Resistance/drug effects
    Chemical Substances Endothelin Receptor Antagonists ; Endothelin-1 ; Phenylpropionates ; Pyridazines ; Receptors, Endothelin ; ambrisentan (HW6NV07QEC)
    Language English
    Publishing date 2007
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2186568-1
    ISSN 1178-2048 ; 1176-6344
    ISSN (online) 1178-2048
    ISSN 1176-6344
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6066: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.

    Barst, Robyn J

    Expert opinion on pharmacotherapy

    2006  Volume 8, Issue 1, Page(s) 95–109

    Abstract: Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult ... ...

    Abstract Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials have demonstrated that sitaxsentan has beneficial effects on exercise capacity (i.e., 6-min walk distance), functional class and hemodynamic parameters in PAH patients. Sitaxsentan has a low incidence of acute hepatotoxicity. Patients on concomitant warfarin require a decrease in warfarin dose to maintain a therapeutic international normalized ratio. The demonstration of clinical efficacy and low incidence of acute hepatotoxicity support the potential use of sitaxsentan for the treatment of PAH.
    MeSH term(s) Endothelin A Receptor Antagonists ; Humans ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/epidemiology ; Hypertension, Pulmonary/physiopathology ; Isoxazoles/pharmacology ; Isoxazoles/therapeutic use ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Receptor, Endothelin A/physiology ; Thiophenes/pharmacology ; Thiophenes/therapeutic use
    Chemical Substances Endothelin A Receptor Antagonists ; Isoxazoles ; Receptor, Endothelin A ; Thiophenes ; sitaxsentan (J9QH779MEM)
    Language English
    Publishing date 2006-12-09
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1517/14656566.8.1.95
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery.

    Rosenzweig, Erika B / Barst, Robyn J

    Progress in cardiovascular diseases

    2012  Volume 55, Issue 2, Page(s) 128–133

    Abstract: Pulmonary arterial hypertension (PAH) with increased pulmonary vascular resistance (PVR), previously termed pulmonary vascular obstructive disease or pulmonary vascular disease is a frequent complication of congenital heart disease (CHD).While there have ...

    Abstract Pulmonary arterial hypertension (PAH) with increased pulmonary vascular resistance (PVR), previously termed pulmonary vascular obstructive disease or pulmonary vascular disease is a frequent complication of congenital heart disease (CHD).While there have been advances in the medical treatments available for classic Eisenmenger syndrome patients who are not suitable for repair, the sub-group of patients with moderate sized congenital systemic to pulmonary shunts and mild to moderately elevated PVR remains challenging. With the development of targeted medical treatments for pulmonary arterial hypertension (PAH), the concept of a combined medical and interventional/surgical approach for patients with PAH associated with CHD (APAH-CHD) has emerged. Careful evaluation and an understanding of the predominant physiologic features will help guide the management of these complex patients and whether late surgical repair is feasible.
    MeSH term(s) Cardiac Surgical Procedures/methods ; Feasibility Studies ; Heart Defects, Congenital/complications ; Heart Defects, Congenital/drug therapy ; Heart Defects, Congenital/surgery ; Humans ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/etiology ; Hypertension, Pulmonary/surgery ; Prognosis ; Time Factors ; Vascular Surgical Procedures/methods ; Vasodilator Agents/therapeutic use
    Chemical Substances Vasodilator Agents
    Language English
    Publishing date 2012-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 209312-1
    ISSN 1873-1740 ; 1532-8643 ; 0033-0620
    ISSN (online) 1873-1740 ; 1532-8643
    ISSN 0033-0620
    DOI 10.1016/j.pcad.2012.07.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 229: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: PDGF signaling in pulmonary arterial hypertension.

    Barst, Robyn J

    The Journal of clinical investigation

    2005  Volume 115, Issue 10, Page(s) 2691–2694

    Abstract: The pathobiology of pulmonary arterial hypertension (PAH) includes endothelial cell dysfunction and proliferation and migration of VSMCs. As PDGF has been implicated in these processes, Schermuly et al. hypothesized that altered PDGF signaling may be ... ...

    Abstract The pathobiology of pulmonary arterial hypertension (PAH) includes endothelial cell dysfunction and proliferation and migration of VSMCs. As PDGF has been implicated in these processes, Schermuly et al. hypothesized that altered PDGF signaling may be involved in the vascular remodeling observed in PAH. To explore this notion further, the authors evaluated the effects of the PDGF receptor inhibitor STI571 in 2 different animal models of pulmonary hypertension. In both models, after development of pulmonary vascular disease, administration of STI571 reversed pulmonary vascular changes. These studies provide preclinical proof of concept for the clinical development of a PDGF inhibitor as a targeted therapy for PAH patients.
    MeSH term(s) Animals ; Benzamides ; Disease Models, Animal ; Humans ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/metabolism ; Imatinib Mesylate ; Piperazines/therapeutic use ; Platelet-Derived Growth Factor/antagonists & inhibitors ; Platelet-Derived Growth Factor/metabolism ; Protein Kinase Inhibitors/therapeutic use ; Pulmonary Artery/metabolism ; Pyrimidines/therapeutic use ; Receptors, Platelet-Derived Growth Factor/metabolism
    Chemical Substances Benzamides ; Piperazines ; Platelet-Derived Growth Factor ; Protein Kinase Inhibitors ; Pyrimidines ; Imatinib Mesylate (8A1O1M485B) ; Receptors, Platelet-Derived Growth Factor (EC 2.7.10.1)
    Language English
    Publishing date 2005-10
    Publishing country United States
    Document type Comment ; Journal Article ; Review
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI26593
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Evaluation and treatment for angina in pulmonary arterial hypertension.

    Barst, Robyn J

    The American journal of medicine

    2004  Volume 116, Issue 6, Page(s) 427–428

    MeSH term(s) Angina Pectoris/diagnosis ; Angina Pectoris/etiology ; Angina Pectoris/therapy ; Coronary Stenosis/diagnosis ; Coronary Stenosis/etiology ; Dilatation, Pathologic ; Humans ; Hypertension, Pulmonary/complications ; Pulmonary Artery/pathology ; Ventricular Dysfunction, Left/prevention & control
    Language English
    Publishing date 2004-03-15
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2004.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.289: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Book: Pulmonary arterial hypertension

    Barst, Robyn J

    diagnosis and evidence-based treatment

    2008  

    Author's details edited by Robyn J. Barst
    MeSH term(s) Hypertension, Pulmonary/diagnosis ; Hypertension, Pulmonary/therapy ; Evidence-Based Medicine/methods ; Pulmonary Artery/pathology
    Language English
    Size xiii, 256 p. :, ill., port.
    Publisher John Wiley & Sons
    Publishing place Chichester, West Sussex ; Hoboken, NJ
    Document type Book
    ISBN 9780470059722 ; 0470059729
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top